journal article·2024-12-09Open access

Improving the Anti-Tumor Effect of Indoleamine 2,3-Dioxygenase Inhibitor CY1-4 by CY1-4 Nano-Skeleton Drug Delivery System

Hui Li, Junwei Liu, Jingru Wang, Zhuoyue Li, Jianming Yu, Xu Huang, Bingchuan Wan, Xiangbao Meng, Xuan Zhang

Journal of Functional Biomaterials· Volume 15· Issue 12

Abstract

Background: CY1-4, 9-nitropyridine [2′,3′:4,5] pyrimido [1,2-α] indole -5,11- dione, is an indoleamine 2,3-dioxygenase (IDO) inhibitor and a poorly water-soluble substance. It is very important to increase the solubility of CY1-4 to improve its bioavailability and therapeutic effect. In this study, the mesoporous silica nano-skeleton carrier material Sylysia was selected as the carrier to load CY1-4, and then the CY1-4 nano-skeleton drug delivery system (MSNM@CY1-4) was prepared by coating the hydrophilic polymer material Hydroxypropyl methylcellulose (HPMC) and the lipid material Distearoylphosphatidyl-ethanolamine-poly(ethylene glycol)2000 (DSPE-PEG2000) to improve the anti-tumor effect of CY1-4. Methods: The solubility and dissolution of MSNM@CY1-4 were investigated, and its bioavailability, anti-tumor efficacy, IDO inhibitory ability and immune mechanism were evaluated in vivo. Results: CY1-4 was loaded in MSNM@CY1-4 in an amorphous form, and MSNM@CY1-4 could significantly improve the solubility (up to about 200 times) and dissolution rate of CY1-4. In vivo studies showed that the oral bioavailability of CY1-4 in 20 mg/kg MSNM@CY1-4 was about 23.9-fold more than that in 50 mg/kg CY1-4 suspension. In B16F10 tumor-bearing mice, MSNM@CY1-4 significantly inhibited tumor growth, prolonged survival time, significantly inhibited IDO activity in blood and tumor tissues, and reduced Tregs in tumor tissues and tumor-draining lymph nodes to improve anti-tumor efficacy. Conclusions: The nano-skeleton drug delivery system (MSNM@CY1-4) constructed in this study is a potential drug delivery platform for improving the anti-tumor effect of oral poorly water-soluble CY1-4.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tryptophan and brain disorders · Cancer-related cognitive impairment studies · Pharmacological Receptor Mechanisms and Effects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Ningbo Institute of Marine Medicine, Peking University, Ningbo 315832, China

Funding

Beijing Natural Science Foundation of China · National Natural Science Foundation of China

References (80)

Show source-provided references
1. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma10.1038/s41591-021-01544-x ↗
2. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status10.1158/2326-6066.CIR-21-0457 ↗
3. Modulation of T cells by tryptophan metabolites in the kynurenine pathway10.1016/j.tips.2023.04.006 ↗
4. Cascade Immune Activation of Self-Delivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor10.1002/smll.202205694 ↗
5. The kynurenine pathway implicated in patient delirium: Possible indications for indoleamine 2,3 dioxygenase inhibitors10.1172/JCI164577 ↗
6. Photoactivatable Immunostimulatory Nanomedicine for Immunometabolic Cancer Therapy10.1021/jacs.2c07872 ↗
7. Huang, D., Wu, T., Lan, S., Liu, C., Guo, Z., and Zhang, W. (2022). In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials, 289.10.1016/j.biomaterials.2022.121808 ↗
8. Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy10.1038/s41467-022-31044-6 ↗
9. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma10.1158/1078-0432.CCR-21-1392 ↗
10. Zhao, H., Wang, Z., Yang, S., Zhang, R., Guo, J., and Yang, D. (2024). Energy-storing DNA-based hydrogel remodels tumor microenvironments for laser-free photodynamic immunotherapy. Biomaterials, 309.10.1016/j.biomaterials.2024.122620 ↗
11. Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy10.1126/sciadv.adn8079 ↗
12. Novel PdPtCu Nanozymes for Reprogramming Tumor Microenvironment to Boost Immunotherapy Through Endoplasmic Reticulum Stress and Blocking IDO-Mediated Immune Escape10.1002/smll.202303596 ↗
13. Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy10.1016/j.apsb.2024.05.010 ↗
14. Fox, E., Oliver, T., Rowe, M., Thomas, S., Zakharia, Y., Gilman, P.B., Muller, A.J., and Prendergast, G.C. (2018). Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Front. Oncol., 8.10.3389/fonc.2018.00370 ↗
15. Nanomedicine and cancer immunotherapy: Focus on indoleamine 2,3-dioxygenase inhibitors10.2147/OTT.S119362 ↗
16. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)10.1021/acs.jmedchem.9b00942 ↗
17. Dhiman, V., Giri, K.K., Zainuddin, M., Rajagopal, S., and Mullangi, R. (2017). Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. Biomed. Chromatogr., 31.10.1002/bmc.3794 ↗
18. Quantification of Linrodostat and its metabolites: Overcoming bioanalytical challenges in support of a discovery Indoleamine 2,3 dioxygenase program10.1016/j.jchromb.2022.123305 ↗
19. Discovery of indoximod prodrugs and characterization of clinical candidate NLG80210.1016/j.ejmech.2020.112373 ↗
20. The efficacy of indoximod upon stimulation with pro-inflammatory cytokines in triple-negative breast cancer cells10.1080/08923973.2021.1953064 ↗
21. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial10.1093/neuonc/noad174 ↗
22. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression10.1016/j.intimp.2024.112437 ↗
23. Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo-Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment10.1002/adma.202307263 ↗
24. Hypoxia-Specific Metal-Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound10.1021/acsnano.4c02921 ↗
25. Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy10.1002/advs.202305382 ↗
26. The therapeutic potential of targeting tryptophan catabolism in cancer10.1038/s41416-019-0664-6 ↗
27. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors10.1016/j.ejmech.2020.112059 ↗
28. Peyraud, F., Guegan, J.P., Bodet, D., Cousin, S., Bessede, A., and Italiano, A. (2022). Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives. Front. Immunol., 13.10.3389/fimmu.2022.807271 ↗
29. Yang, C., Ng, C.T., Li, D., and Zhang, L. (2021). Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation. Front. Immunol., 12.10.3389/fimmu.2021.725204 ↗
30. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy10.1016/j.bioorg.2018.02.010 ↗
31. Wen, H., Liu, Y., Wang, S., Wang, T., Zhang, G., Chen, X., Li, Y., Cui, H., Lai, F., and Sheng, L. (2019). Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents. Molecules, 24.10.3390/molecules24112124 ↗
32. Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing10.1021/acs.jmedchem.1c01670 ↗
33. Liu, X., Wang, H., Li, Z., Li, J., He, S., Hu, C., Song, Y., Gao, H., and Qin, Y. (2024). Transformable self-delivered supramolecular nanomaterials combined with anti-PD-1 antibodies alleviate tumor immunosuppression to treat breast cancer with bone metastasis. J. Nanobiotechnol., 22.10.1186/s12951-024-02839-0 ↗
34. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway10.1002/adma.202102188 ↗
35. Overcoming Chemoimmunotherapy-Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension10.1002/advs.202102043 ↗
36. Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer10.1002/advs.201903332 ↗
37. An Activatable Dual Polymer Nanosystem for Photoimmunotherapy and Metabolic Modulation of Deep-Seated Tumors10.1002/adhm.202303305 ↗
38. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix10.1080/10717544.2016.1245371 ↗
39. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid10.2147/IJN.S240436 ↗
40. Meng, X.B., Chen, Y., Li, Z.J., and Zhang, M.Q. (2017). Nitrogen Heterocyclic Tryptamine Ketone Derivative and Application as IDO1 and TDO Inhibitor. (CN107260743A).
41. Self-Splittable Transcytosis Nanoraspberry for NIR-II Photo-Immunometabolic Cancer Therapy in Deep Tumor Tissue10.1002/advs.202204067 ↗
42. Tumor Microenvironment Activated Photoacoustic-Fluorescence Bimodal Nanoprobe for Precise Chemo-immunotherapy and Immune Response Tracing of Glioblastoma10.1021/acsnano.3c03378 ↗
43. Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression10.1016/j.apsb.2024.05.032 ↗
44. Dai, L.L., Li, X., Yao, M.J., Niu, P.Y., Yuan, X.C., Li, K., Chen, M.W., Fu, Z.X., Duan, X.L., and Liu, H.B. (2020). Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy. Biomaterials, 241.10.1016/j.biomaterials.2020.119901 ↗
45. Paraptosis Inducer to Effectively Trigger Immunogenic Cell Death for Metastatic Tumor Immunotherapy with IDO Inhibition10.1021/acsnano.2c11964 ↗
46. Li, Z., Wang, J., Liu, J., Yu, J., Wang, J., Wang, H., Wei, Q., Liu, M., Xu, M., and Feng, Z. (2024). Multifunctional ZnO@DOX/ICG-LMHP Nanoparticles for Synergistic Multimodal Antitumor Activity. J. Funct. Biomater., 15.10.3390/jfb15020035 ↗
47. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy10.1016/j.actbio.2022.07.022 ↗
48. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance10.1016/j.it.2016.01.002 ↗
49. Meireson, A., Devos, M., and Brochez, L. (2020). IDO Expression in Cancer: Different Compartment, Different Functionality?. Front. Immunol., 11.10.3389/fimmu.2020.531491 ↗
50. Combination strategies to maximize the benefits of cancer immunotherapy10.1186/s13045-021-01164-5 ↗
51. Amino acid metabolism in immune cells: Essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy10.1186/s13045-023-01453-1 ↗
52. Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., and Székvölgyi, L. (2018). The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front. Immunol., 9.10.3389/fimmu.2018.00151 ↗
53. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth10.1136/jitc-2021-003623 ↗
54. Guo, Y.X., Liu, Y., Wu, W., Ling, D.S., Zhang, Q., Zhao, P., and Hu, X. (2021). Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials, 276.10.1016/j.biomaterials.2021.121018 ↗
55. Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems10.1016/j.ijpharm.2017.06.007 ↗
56. Low-Field NMR to Characterize the Crystalline State of Ibuprofen Confined in Ordered or Nonordered Mesoporous Silica10.1248/cpb.c22-00180 ↗
57. Impact of HPMC on inhibiting crystallization and improving permeability of curcumin amorphous solid dispersions10.1016/j.carbpol.2017.12.004 ↗
58. Ultrasmall Cu(I) Nanoparticles Stabilized on Surface of HPMC: An Efficient Catalyst for Fast and Organic Solvent-Free Tandem Click Chemistry in Water10.1002/cssc.202201826 ↗
59. Touqeer, S.I., Jahan, N., Abbas, N., and Ali, A. (2022). Formulation and Process Optimization of Rauvolfia serpentina Nanosuspension by HPMC and In Vitro Evaluation of ACE Inhibitory Potential. J. Funct. Biomater., 13.10.3390/jfb13040268 ↗
60. Jahan, N., Kousar, F., Rahman, K.U., Touqeer, S.I., and Abbas, N. (2023). Development of Nanosuspension of Artemisia absinthium Extract as Novel Drug Delivery System to Enhance Its Bioavailability and Hepatoprotective Potential. J. Funct. Biomater., 14.10.3390/jfb14080433 ↗
61. Montelukast microsuspension with hypromellose for improved stability and oral absorption10.1016/j.ijbiomac.2021.05.151 ↗
62. Paclitaxel-loaded magnetic nanocrystals for tumor neovascular-targeted theranostics: An amplifying synergistic therapy combining magnetic hyperthermia with chemotherapy10.1039/D0NR08197C ↗
63. Nguyen, T.T., Duong, V.A., and Maeng, H.J. (2021). Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics, 13.10.3390/pharmaceutics13071103 ↗
64. Vrettos, N.N., Roberts, C.J., and Zhu, Z. (2021). Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics, 13.10.3390/pharmaceutics13101591 ↗
65. Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP(swe)/PS1(ΔE9) transgenic mice for the diagnosis of Alzheimer’s disease10.1039/D0TB01101K ↗
66. Mixed polyethylene glycol-modified breviscapine-loaded solid lipid nanoparticles for improved brain bioavailability: Preparation, characterization, and in vivo cerebral microdialysis evaluation in adult Sprague Dawley rats10.1208/s12249-014-0080-4 ↗
67. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges10.2147/DDDT.S373780 ↗
68. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration10.1158/1078-0432.CCR-23-0535 ↗
69. A phase I study of indoximod in patients with advanced malignancies10.18632/oncotarget.8216 ↗
70. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma10.1007/s10637-020-00950-1 ↗
71. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies10.1158/1078-0432.CCR-16-2272 ↗
72. Oral administration of nanoformulated indoximod ameliorates ulcerative colitis by promoting mitochondrial function and mucosal healing10.1016/j.ijpharm.2023.122813 ↗
73. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles10.1016/j.phrs.2017.09.004 ↗
74. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy10.1021/acsami.4c02740 ↗
75. Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer10.1186/s12943-024-02164-y ↗
76. IDO/kynurenine pathway in cancer: Possible therapeutic approaches10.1186/s12967-022-03554-w ↗
77. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase10.1177/11786469221138456 ↗
78. Chen, X., Xu, D., Yu, J., Song, X.J., Li, X., and Cui, Y.L. (2024). Tryptophan Metabolism Disorder-Triggered Diseases, Mechanisms, and Therapeutic Strategies: A Scientometric Review. Nutrients, 16.10.3390/nu16193380 ↗
79. Inhibiting IDO pathways to treat cancer: Lessons from the ECHO-301 trial and beyond10.1007/s00281-018-0702-0 ↗
80. Kim, M., and Tomek, P. (2021). Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Front. Immunol., 12.10.3389/fimmu.2021.636081 ↗